Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of dunning R-3327H prostate cancer model
- 1 January 1985
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 6 (3) , 219-232
Abstract
The therapy for the treatment of prostate cancer and other sex-steroid-dependent tumors based on agonists of LH-RH has been made more practical and efficacious by the development of a long-acting formulation of microcapsules of D-Trp-6-LH-RH for controlled release. Antiandrogens, which neutralize the effect of endogenous androgens, have been used also in the management of prostate cancer in man. The effects of a simultaneous administration of the antiandrogen flutamide and microcapsules of the agonist D-Trp-6-LH-RH were studied in the Dunning R-3327H rat prostate adenocarcinoma model to determine whether the combination of these two drugs might inhibit tumor growth more effectively than single agents. Microcapsules of D-Trp-6-LH-RH, calculated to release a controlled dose of 25 μg/day for a period of 30 days were injected intramuscularly once a month. Flutamide was administered SC at a daily dose of 25 mg/kg. The therapy was started 100 days after the tumor transplantation and continued for 60 days. Tumor weights and volumes were significantly reduced in rats treated with microcapsules or flutamide alone, but the former drug inhibited tumor growth more than the latter. The combined treatment of flutamide and microcapsules significantly decreased tumor weight and volume, but did not exert a synergistic effect on tumor growth, the reduction being smaller for the combination than for the microcapsules alone. There was a significant elevation of serum testosterone, LH, and prolactin in rats treated with flutamide. On the other hand, in rats given microcapsules of D-Trp-6-LH-RH, testosterone fell to castration levels within 7 days and remained at nondetectable values, serum LH and prolactin levels being also suppressed in this group. The combined administration of microcapsules and flutamide also significantly decreased serum testosterone to nondetectable levels by day 7 and suppressed serum LH and prolactin. Our findings raise doubts of whether the daily administration of the combination of LH-RH agonist with an antiandrogen offers an advantage over the use of microcapsules of an agonist like D-Trp-6-LH-RH alone in the treatment of prostatic carcinoma.Keywords
This publication has 47 references indexed in Scilit:
- Antagonistic effect of androgen on prostatic cell deathThe Prostate, 1984
- Gonadotropin-Releasing Hormone Analogues for Prostate Cancer: Untoward Side Effects of High-Dose Regimens Acquire a Therapeutical DimensionEuropean Urology, 1982
- Early combined hormonal and chemotherapy for metastatic carcinoma of prostateUrology, 1980
- Hormonal Effects on Cell Proliferation in Rat Prostate1976
- The effects of testosterone, 5α-dihydrotestosterone and adenosine 3′,5′-monophosphate on cell proliferation and differentiation in RAT prostateBiochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis, 1973
- Ultrastructural studies on prostatic involution in the rat. Mechanism of autophagy in epithelial cells, with special reference to the rough-surfaced endoplasmic reticulumJournal of Ultrastructure Research, 1971
- Androgen-Stimulated Restoration in Rat Seminal Vesicle and Prostate Epithelial CellsEndocrinology, 1969
- Polymerization of deoxyribonucleotides in relation to androgen-induced prostatic growthArchives of Biochemistry and Biophysics, 1968
- The Fine Structure and Histochemistry of Prostatic Glands in Relation to Sex Hormones1966
- THE EFFECTS OF CASTRATION AND ANDROGEN REPLACEMENT ON THE NUCLEIC ACID COMPOSITION, METABOLISM, AND ENZYMATIC CAPACITIES OF THE RAT VENTRAL PROSTATEEndocrinology, 1958